医療レポート：Acute Myeloid Leukemia-疫学予測（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Increased age is associated with increased risk and worsened prognosis 12
3.2.2 Smoking increases risk of M2 AML 13
3.2.3 APL is more common among Spanish and Italian origins 14
3.2.4 Chemotherapy and radiation therapy increases risk of AML 14
3.2.5 Benzene increases risk of AML 15
3.3 Global Trends 16
3.3.1 Incidence 16
3.3.2 Survival and Prevalence 18
3.3.3 Subtypes and Mutations 19
3.3.4 Risk Groups 21
3.4 Forecast Methodology 24
3.4.1 Sources Used 25
3.4.2 Forecast Assumptions and Methods 31
3.4.3 Sources Not Used 36
3.5 Epidemiological Forecast of Acute Myeloid Leukemia (2012–2022) 36
3.5.1 Incident Cases of AML 36
3.5.2 Incident Cases of AML by Age 38
3.5.3 Incident Cases of AML by Sex 40
3.5.4 Age-Standardized Incidence of AML 42
3.5.5 Incident Cases of AML Subtypes 43
3.5.6 Incident Cases of AML Subtypes by Age 46
3.5.7 Incident Cases of AML with Mutations in the FLT3 Gene 48
3.5.8 Incident Cases of AML by Risk Group Classifications 49
3.5.9 Five-Year Prevalent Cases of AML 53
3.5.10 Five-Year Prevalent Cases of AML by Age 56
3.5.11 Five-Year Prevalent Cases of APL and MDS/Therapy-Related AML 57
3.5.12 Five-Year Prevalent Cases of APL and MDS/Therapy-Related AML by Age 59
3.6 Discussion 62
3.6.1 Epidemiological Forecast Insight 62
3.6.2 Limitations of the Analysis 62
3.6.3 Strengths of the Analysis 63
4 Appendix 64
4.1 Bibliography 64
4.2 About the Authors 71
4.2.1 Epidemiologists 71
4.2.2 Reviewers 71
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 73
4.2.4 Global Head of Healthcare 73
4.3 About GlobalData 74
4.4 About EpiCast 74
4.5 Disclaimer 75